Tredje AP fonden Reduces Stock Holdings in Humana Inc. (NYSE:HUM)

Tredje AP fonden lowered its position in Humana Inc. (NYSE:HUM) by 24.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,483 shares of the insurance provider’s stock after selling 10,000 shares during the quarter. Tredje AP fonden’s holdings in Humana were worth $7,734,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in HUM. Pzena Investment Management LLC increased its position in shares of Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after buying an additional 1,103,132 shares in the last quarter. FMR LLC increased its position in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Humana by 55.6% during the 3rd quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock worth $190,145,000 after purchasing an additional 214,535 shares in the last quarter. Retirement Systems of Alabama increased its position in Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after purchasing an additional 192,801 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC purchased a new stake in Humana during the 3rd quarter worth about $50,102,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.32% of the stock is owned by company insiders.

Humana Price Performance

HUM stock opened at $251.32 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The stock’s 50 day moving average is $271.56 and its two-hundred day moving average is $281.21. The company has a market capitalization of $30.33 billion, a PE ratio of 25.26, a P/E/G ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.41%. Humana’s dividend payout ratio is presently 35.58%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HUM. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. JPMorgan Chase & Co. dropped their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley lowered their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.